π£ VC round data is live. Check it out!
- Public Comps
- Abeona Therapeutics
Abeona Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Abeona Therapeutics and similar public comparables like Surrozen, Replimune Group, Neumora Therapeutics, Bicycle Therapeutics and more.
Abeona Therapeutics Overview
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Companyβs development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Founded
1974
HQ

Employees
136
Website
Financials (LTM)
EV
$170M
Valuation Multiples
Start free trialAbeona Therapeutics Financials
Abeona Therapeutics reported last 12-month revenue of $26M.
In the same LTM period, Abeona Therapeutics generated $21M in gross profit and $30M in net income.
Revenue (LTM)
Abeona Therapeutics P&L
In the most recent fiscal year, Abeona Therapeutics reported revenue of $6M and EBITDA of $79M.
Abeona Therapeutics is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of 1350%, and net margin of 1223%.
Financial data powered by Morningstar, Inc.
Abeona Therapeutics Stock Performance
Abeona Therapeutics has current market cap of $336M, and enterprise value of $170M.
Market Cap Evolution
Abeona Therapeutics' stock price is $5.91.
Abeona Therapeutics share price increased by 8.5% in the last 30 days, and decreased by 5.3% in the last year.
Abeona Therapeutics has an EPS (earnings per share) of $1.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $170M | $336M | 2.3% | 8.5% | 15.4% | -5.3% | $1.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbeona Therapeutics Valuation Multiples
Abeona Therapeutics trades at 6.4x EV/Revenue multiple, and 2.2x EV/EBITDA.
EV / Revenue (LTM)
Abeona Therapeutics Financial Valuation Multiples
As of May 9, 2026, Abeona Therapeutics has market cap of $336M and EV of $170M.
Abeona Therapeutics has a P/E ratio of 11.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abeona Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Abeona Therapeutics Margins & Growth Rates
Abeona Therapeutics grew revenue by 1002% but net profit decreased by 164% in the last fiscal year.
In the most recent fiscal year, Abeona Therapeutics reported gross margin of 41%, EBITDA margin of 1350%, and net margin of 1223%.
Abeona Therapeutics Margins
Abeona Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Operational KPIs
Abeona Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Competitors
Abeona Therapeutics competitors include Surrozen, Replimune Group, Neumora Therapeutics, Bicycle Therapeutics, Lavipharm, Immuneering, Cuorips, Tanvex BioPharma, DiaMedica and Lineage Cell Therapeutics.
Most Abeona Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 67.8x | 52.3x | (5.7x) | β | |||
| β | 124.8x | (0.6x) | (0.7x) | |||
| β | β | (1.0x) | (1.2x) | |||
| (2.9x) | (3.8x) | 1.0x | 1.0x | |||
| 5.0x | β | 21.5x | β | |||
| β | β | (2.9x) | β | |||
| 256.6x | β | (94.0x) | β | |||
| 27.7x | β | (10.2x) | β | |||
This data is available for Pro users. Sign up to see all Abeona Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abeona Therapeutics
| When was Abeona Therapeutics founded? | Abeona Therapeutics was founded in 1974. |
| Where is Abeona Therapeutics headquartered? | Abeona Therapeutics is headquartered in United States. |
| How many employees does Abeona Therapeutics have? | As of today, Abeona Therapeutics has over 136 employees. |
| Who is the CEO of Abeona Therapeutics? | Abeona Therapeutics' CEO is Vishwas Seshadri. |
| Is Abeona Therapeutics publicly listed? | Yes, Abeona Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Abeona Therapeutics? | Abeona Therapeutics trades under ABEO ticker. |
| When did Abeona Therapeutics go public? | Abeona Therapeutics went public in 1980. |
| Who are competitors of Abeona Therapeutics? | Abeona Therapeutics main competitors include Surrozen, Replimune Group, Neumora Therapeutics, Bicycle Therapeutics, Lavipharm, Immuneering, Cuorips, Tanvex BioPharma, DiaMedica, Lineage Cell Therapeutics. |
| What is the current market cap of Abeona Therapeutics? | Abeona Therapeutics' current market cap is $336M. |
| What is the current revenue of Abeona Therapeutics? | Abeona Therapeutics' last 12 months revenue is $26M. |
| What is the current revenue growth of Abeona Therapeutics? | Abeona Therapeutics revenue growth (NTM/LTM) is 256%. |
| What is the current EV/Revenue multiple of Abeona Therapeutics? | Current revenue multiple of Abeona Therapeutics is 6.4x. |
| Is Abeona Therapeutics profitable? | Yes, Abeona Therapeutics is net-income-positive (as of the last 12 months). |
| What is the current net income of Abeona Therapeutics? | Abeona Therapeutics' last 12 months net income is $30M. |
| How many companies Abeona Therapeutics has acquired to date? | Abeona Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Abeona Therapeutics has invested to date? | Abeona Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Abeona Therapeutics
Lists including Abeona Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.